In a press release on 7 September 2010, Icelandic generics’ manufacturer Actavis announced that it plans to enter into the field of biosimilars with an agreement with Polish biotechnology company, Bioton.
Actavis plans entry to biosimilars market with Bioton agreement
Home/Pharma News
|
Posted 24/09/2010
0
Post your comment

The agreement will involve the sale of 51% of Bioton’s shares in Biopartners Holdings to Actavis, giving it a majority share in the company.
Biopartners is a Swiss-based biopharmaceutical company. Its recombinant human growth hormone (rhGH), Valtropin, was one of the first biosimilars to receive marketing authorisation from the EMA. Biopartners is also on track to be the first company to submit a sustained-release formulation of rhGH, which will cut the number of self-administered injections from once-a-day to once-a-week - a major breakthrough in hGH treatment.
Actavis CEO, Dr Claudio Albrecht, commented that “by entering into biosimilars the generic companies gain access to a portfolio that requires a new approach to development and marketing. We will have generic companies investing significantly more in research and we will see originator companies developing generics. Only the large generic players such as Teva, Sandoz, Mylan and Actavis have the capability to do this, either by themselves or in partnership with originators”.
Actavis have stated that they want to be selective with their biologic target portfolio, highlighting endocrinology (a branch of biology and medicine dealing with the endocrine system), oncology and insulin as areas of interest for them.
Actavis has until 1 November 2010 to perform its due diligence of Biopartners and finalise the agreement.
Actavis is the latest in a string of generics companies looking to gain a foothold in the, what promises to be, lucrative biosimilars market.
Related articles
Cipla enters the biosimilars market
References
Actavis Press Releases. Actavis plans to enter into Biosimilars. 7 September 2010.
Bioton Investor Reports. Current report 2010/53 dated 06.09.2010. Confidential information (conclusion of agreement between BIOTON S.A. and Actavis Group Hf). 6 September 2010.
Guidelines
FDA issues guidance on AI use in drug and biologicals regulatory decision making
ICH adopts Good Clinical Practice Guideline for clinical trials
Policies & Legislation
NPRA Malaysia trials new timelines for variation applications
Regulatory evolution and impact of simplified requirements for interchangeable biosimilars in the US
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
Bio-Thera partners with Tabuk in Saudi Arabia and SteinCares in LATAM
Klinge-Teva and MS Pharma agreements for Eylea and Stelara biosimilars in Europe and MENA
Biosimilars thrive as China’s biotech industry gains momentum
Greener Pharmaceuticals: WHO's call for innovative regulatory practices and eco-friendly innovations
Bio-Thera partners with Tabuk in Saudi Arabia and SteinCares in LATAM

Home/Pharma News Posted 18/02/2025
Klinge-Teva and MS Pharma agreements for Eylea and Stelara biosimilars in Europe and MENA

Home/Pharma News Posted 06/02/2025
Greener Pharmaceuticals: WHO's call for innovative regulatory practices and eco-friendly innovations

Home/Pharma News Posted 15/01/2025
The best selling biotechnology drugs of 2008: the next biosimilars targets

Post your comment